Loading...

NGNE NEUROGENE INC Expansion Plans 8-K Filing

NRGN

NGN

NEUROGENE INC

(NGNE)

2025 8-K

Dosing Completion

Annual Meeting Results

Quarterly Results Released

Board Expansion

Financial Results Announced

Breakthrough Designation

Corporate Updates Announcement

Quarterly Results Update

Positive Trial Results

Patient Dosing Initiated

FDA Protocol Update

Registrar Trials

Amendments to Plans

Other Special Situation

Financial Statements

Management Agreement

Financial Results

Corporate Update

Clinical Trial Update

Financial Results

Clinical Trial Update

Private Placement

Earnings Reports

Regulatory Approval

Regulation FD Disclosure

Annual Meeting of Stockholders

Regulation FD Disclosure

Earnings Reports

Gene Therapy Clinical Trial...

Departure of Directors or C...

Departure of Directors or C...

Earnings Reports

Regulation FD Disclosure

Appointment of Senior Vice ...

Press Release and Corporate...

Merger and Name Change

Merger Supplemental Disclos...

Revised CVR Agreement

Reverse Stock Split

Merger of Equals

Annual Meeting of Stockholders

Appointment of Officers

Restructuring and CEO Resig...

Strategic Review Announcement

External Links:

On November 12, 2025, Neurogene Inc. reported positive interim clinical data for its NGN-401 gene therapy aimed at treating Rett syndrome in children aged 4-10. This filing is significant as it reflects advancements in the company's clinical trial progress.

AI Assistant

NEUROGENE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.